Summary
88%
|
Pharmacokinetic
|
0% | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aflibercept | |||||||||||
| Scores | 0% | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
QT time prolongation
| |||||||||||
|
Anticholinergic effects
| |||||||||||
|
Serotonergic effects
| |||||||||||
|
Adverse drug events
|
-12% | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | |||||||||||
| Diarrhea | |||||||||||
| Leukopenia | |||||||||||
Variants ✨
For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Intended use
Aflibercept is used to treat wet macular degeneration (AMD) or metastatic colorectal cancer. To do this, it is either introduced directly into the eye (AMD) or administered intravenously. Aflibercept is a recombinant (genetically engineered) fusion protein (a composite protein molecule) and blocks the activation of the VEGF receptors and the proliferation (growth and maturation) of the endothelial cells, which prevents the growth of new vessels that supply tumors with oxygen and nutrients.
Pharmacokinetics
-0%
| ∑ Exposurea | afl | |
|---|---|---|
| Aflibercept | 1 |
Symbol (a): x-fold change in AUC
Legend (n.a.): Information not available
Legend (n.a.): Information not available
Since only aflibercept was entered without any further substances, no pharmacokinetic interactions can be detected.
Rating:
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of aflibercept is unknown. Protein binding [Pb] is not known. The metabolism does not take place via the common cytochromes.
Serotonergic effects
-0%
| Scores | ∑ Points | afl |
|---|---|---|
| Serotonergic Effects a | 0 | Ø |
Symbol (a): Increased risk from 5 points.
Rating: According to our knowledge, aflibercept does not increase serotonergic activity.
Anticholinergic effects
-0%
| Scores | ∑ Points | afl |
|---|---|---|
| Kiesel b | 0 | Ø |
Symbol (b): Increased risk from 3 points.
Rating: According to our findings, aflibercept does not increase anticholinergic activity.
QT time prolongation
-0%
We do not know of any QT-prolonging potential for aflibercept.
General adverse effects
-12%
| Side effects | ∑ frequency | afl |
|---|---|---|
| Neutropenia | 37.0 % | 37.0 |
| Diarrhea | 19.0 % | 19.0 |
| Leukopenia | 16.0 % | 16.0 |
| Stomatitis | 13.0 % | 13.0 |
| Fatigue | 13.0 % | 13.0 |
| Infection | 12.3 % | 12.3 |
| Blurred vision | 10.0 % | 10.0 |
| Pain in eye | 10.0 % | 10.0 |
| Retinal hemorrhage | 10.0 % | 10.0 |
| Proteinuria | 8.0 % | 8.0 |
Tabular extract of the most common side effects
Sign (+): side effect described, but frequency not known
Sign (↑/↓): frequency rather higher / lower due to exposure
Sign (+): side effect described, but frequency not known
Sign (↑/↓): frequency rather higher / lower due to exposure
Neurological
Asthenia (5%): aflibercept
Ophthalmological
Cataract: aflibercept
Glaucoma: aflibercept
Uveitis: aflibercept
Limitations
Based on your
References
No literature information available.
